Beatriz Abascal-Bolado

Dr. Beatriz Abascal-Bolado


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MHManuel Herrero-Montes
Manuel Herrero-Montes
César Fernandez-de-las-PeñasCésar Fernandez-de-las-Peñas
César Fernandez-de-las-Peñas
DFDiego Ferrer-Pargada
Diego Ferrer-Pargada
SISheila Izquierdo-Cuervo
Sheila Izquierdo-Cuervo
BABeatriz Abascal-Bolado
Beatriz Abascal-Bolado
Paula Parás-BravoPaula Parás-Bravo
Paula Parás-Bravo
Pain symptoms after the acute phase of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are present in almost 50% of COVID-19 survivors. The presence of kinesiophobia is a risk factor which may promote and perpetuate pain. This study aimed to investigate variables associated with the presence of kinesiophobia in a sample of previously hospitalized COVID-19 survivors exhibiting post-COVID pain. An observational study was conducted in three urban hospitals in Spain, including one hundred and forty-six COVID-19 survivors with post-COVID pain. Demographic (age, weight, height), clinical (intensity and duration of pain), psychological (anxiety level, depressive level, sleep quality), cognitive (catastrophizing), sensitization-associated symptoms, and health-related quality of life variables were collected in 146 survivors with post-COVID pain, as well as whether they exhibited kinesiophobia. Stepwise multiple linear regression models were conducted to identify variables significantly associated with kinesiophobia. Patients were assessed a mean of 18.8 (SD 1.8) months after hospital discharge. Kinesiophobia levels were positively associated with anxiety levels (r: 0.356, p < 0.001), depression levels (r: 0.306, p < 0.001), sleep quality (r: 0.288, p < 0.001), catastrophism (r: 0.578, p < 0.001), and sensitization-associated symptoms (r: 0.450, p < 0.001). The stepwise regression analysis revealed that 38.1% of kinesiophobia variance was explained by catastrophism (r2 adj: 0.329, B = 0.416, t = 8.377, p < 0.001) and sensitization-associated symptoms (r2 adj: 0.381, B = 0.130, t = 3.585, p < 0.001). Kinesiophobia levels were associated with catastrophism and sensitization-associated symptoms in previously hospitalized COVID-19 survivors with post-COVID pain. Identification of patients at a higher risk of developing a higher level of kinesiophobia, associated with post-COVID pain symptoms, could lead to better therapeutic strategies.

Verified
Journal Article
Open access
PDF file
VCVerónics Pulito Cueto
Verónics Pulito Cueto
MMMaría Sebastián Mora-Gil
María Sebastián Mora-Gil
DFDiego Ferrer-Pargada
Diego Ferrer-Pargada
SRSara Remuzgo-Martínez
Sara Remuzgo-Martínez
FGFernanda Genre
Fernanda Genre
JCJosé Manuel Cifrián
José Manuel Cifrián
The most critical forms of coronavirus disease 2019 (COVID-19) are associated with excessive activation of the inflammasome. Despite the COVID-19 impact on public health, we still do not fully understand the mechanisms by which the inflammatory response influences disease prognosis. Accordingly, we aimed to elucidate the role of polymorphisms in the key genes of the formation and signaling of the inflammasome as biomarkers of COVID-19 severity. For this purpose, a large and well-defined cohort of 377 COVID-19 patients with mild (n = 72), moderate (n = 84), severe (n = 100), and critical (n = 121) infections were included. A total of 24 polymorphisms located in inflammasome-related genes (NLRP3, NLRC4, NLRP1, CARD8, CASP1, IL1B, IL18, NFKB1, ATG16L1, and MIF) were genotyped in all of the patients and in the 192 healthy controls (HCs) (who were without COVID-19 at the time of and before the study) by RT-qPCR. Our results showed that patients with mild, moderate, severe, and critical COVID-19 presented similar allelic and genotypic distribution in all the variants studied. No statistically significant differences in the haplotypic distribution of NLRP3, NLRC4, NLRP1, CARD8, CASP1, IL1B, and ATG16L1 were observed between COVID-19 patients, who were stratified by disease severity. Each stratified group of patients presented a similar genetic distribution to the HCs. In conclusion, our results suggest that the inflammasome polymorphisms studied are not associated with the worsening of COVID-19.

25 March 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
MSMiguel Santibáñez
Miguel Santibáñez
ARAdriana Núñez Robainas
Adriana Núñez Robainas
ESTHER BARREIROESTHER BARREIRO
ESTHER BARREIRO
AEAndrea Expósito
Andrea Expósito
JCJUAN AGUERO CALVO
JUAN AGUERO CALVO
IOIgnacio Fernández Olmo
Ignacio Fernández Olmo
Inflammatory cell activation in asthma may lead to reactive oxygen species (ROS) overproduction with an imbalance between oxidant levels and antioxidant capacity, called oxidative stress (OS). Since particulate matter (PM) airborne exposure may also contribute to ROS generation, it is unclear whether PM contributes more to OS than inflammatory cell activation. In our ASTHMA-FENOP study, which included 44 asthma patients and 37 matched controls, we aimed to characterize OS using five serum markers: total ROS content, protein carbonyl content, oxidized low-density lipoprotein (OxLDL), 8-hydroxydeoxyguanosine, and glutathione. Volunteers wore personal samplers for 24 h, collecting fine and coarse PM fractions separately, and the oxidative potential (OP) was determined using two methods. We observed differences between asthmatic and non-asthmatic volunteers in some OS markers, such as OxLDL, with an adjusted mean difference of 50,059.8 ng/mL (p < 0.001). However, we did not find an association between higher PM-OP and increased systemic OS. This suggests that at our PM-OP exposure levels, OS generated by the inflammatory cells themselves is more relevant than that generated by airborne PM. This supports the idea that asthma is a heterogeneous disease at the molecular level, mediated by inflammatory cell activation, and that OS may have potential clinical implications.

28 November 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
MSMiguel Santibáñez
Miguel Santibáñez
JRJuan José Ruiz-Cubillán
Juan José Ruiz-Cubillán
AEAndrea Expósito
Andrea Expósito
JCJUAN AGUERO CALVO
JUAN AGUERO CALVO
JGJuan Luis García-Rivero
Juan Luis García-Rivero
IOIgnacio Fernández Olmo
Ignacio Fernández Olmo
With the rationale that the oxidative potential of particulate matter (PM-OP) may induce oxidative stress and inflammation, we conducted the ASTHMA-FENOP study in which 44 asthmatic patients and 37 matched controls wore a personal sampler for 24 h, allowing the collection of fine and coarse PM fractions separately, to determine PM-OP by the dithiothreitol (DTT) and ascorbic acid (AA) methods. The levels of Interleukin 6 (IL-6) and the IL-6/IL-10 ratio, as indicators of pro- and anti-inflammatory statuses, were determined by calculating the mean differences (MDs), odds ratios (ORs) and p-trends adjusted for sex, age, study level and body mass index. Positive associations for IL-6 levels in the form of adjusted MDs and ORs were obtained for all PM-OP metrics, reaching statistical significance for both OP-DTT and OP-AA in the fine fraction, with adjusted OR = 5.66; 95%CI (1.46 to 21.92) and 3.32; 95%CI (1.07 to 10.35), respectively, along with statistically significant dose–response patterns when restricting to asthma and adjusted also for clinical variables (adjusted p-trend = 0.029 and 0.01). Similar or stronger associations and dose–response patterns were found for the IL-6/IL-10 ratio. In conclusion, our findings on the effect of PM-OP on systemic inflammation support that asthma is a heterogeneous disease at the molecular level, with PM-OP potentially playing an important role.

25 March 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
JGJuan Luis García-Rivero
Juan Luis García-Rivero
AAAdil Hannaoui Anaaoui
Adil Hannaoui Anaaoui
APAbel Pallarés-Sanmartín
Abel Pallarés-Sanmartín
MAMARINA BLANCO APARICIO
MARINA BLANCO APARICIO
RGRaquel García-Hernáez
Raquel García-Hernáez
MSMiguel Santibáñez
Miguel Santibáñez
Background: Clinical remission has become a realistic treatment goal in severe asthma, but current evidence mostly reports global remission rates without accounting for baseline disease burden. No simple tool exists to quantify baseline severity and estimate an individual patient’s probability of achieving remission under biologic therapy. Methods: This prospective observational study included 93 adults with severe asthma initiating tezepelumab across 14 specialised severe asthma units in Spain. Four baseline domains—poor symptom control (ACT < 20), ≥1 severe exacerbation in the previous 12 months, maintenance oral corticosteroid (OCS) use, and FEV1 < 80% predicted—were used to construct an empirically weighted composite score (Base4Score) based on the inverse probability of correcting each abnormal domain at 12 months. Strict clinical remission at 12 months was defined as ACT ≥ 20, no severe exacerbations, no maintenance OCS, and FEV1 ≥ 80%. Logistic regression was used to assess the association between the score and non-remission, adjusting for age, sex, smoking status, T2 phenotype, and biologic-naive status. Results: Of 93 treated patients, 81 had complete baseline data for Base4Score derivation and 77 had complete 12-month data for strict clinical remission analysis. Strict clinical remission was achieved in 16/77 patients (20.8%). Remission rates decreased across increasing baseline score strata: 40.0% for scores < 5, 17.6% for scores 5 to <9, and 12.5% for scores ≥ 9 (linear p-trend = 0.022). Each 1-point increase in the continuous Base4Score was associated with higher adjusted odds of non-remission (OR 1.22; 95% CI 1.00–1.49; p = 0.047), and patients with scores ≥ 9 had approximately sevenfold higher adjusted odds of non-remission than those with scores < 5 (OR 6.77; 95% CI 1.40–32.84; p = 0.018). Conclusions: The Base4Score is a simple, empirically derived baseline severity index that predicts 12-month strict clinical remission in severe asthma treated with tezepelumab. If externally validated, it could help personalise expectations, optimise timing of biologic initiation and guide treat-to-target strategies in severe asthma.

7 September 2020 in European Respiratory Journal
Verified
Conference Paper
Closed access
BABeatriz Abascal-Bolado
Beatriz Abascal-Bolado
LMLaura Sanchez Moreno
Laura Sanchez Moreno
TLTeresa Diaz De Teran Lopez
Teresa Diaz De Teran Lopez
PCPablo Lozano Cuesta
Pablo Lozano Cuesta
VGVictoria Maderuelo Garcia
Victoria Maderuelo Garcia
CLClaudia Loidi Lopez
Claudia Loidi Lopez
The correlation between nutritional status and survival in patient with organ malignancies, including lung cancer, is well done. Previous studies supported the use of the Geriatric Nutritional Risk Index (GNRI) as a survival prognostic factor due to the significant association with nutritional parameters and both, short and long-term outcomes. The main aim of this study is to evaluate the GNRI as an independent prognostic factor of survival in geriatric patients with lung cancer who underwent pulmonary resection. Methods: Retrospective study (2010-2018) that included geriatric patients (>65 years) with major elective pulmonary resection for lung cancer. Clinical characteristics, management and outcomes were colleted. The GNRI score was calculated as 1.487 serum albumin concentration (g/L) + 41.7 preoperative body weight/ideal body weight (kg). Patients were divided in group A (GNRI>98) and grupo B (≤98), this group was at risk of malnutrition. Univariate survival analysis was undertaken using the log-rank test. Cox regression multivariate analysis was carried out accounting for different variables. Results: 341 patients were included, 326 in Group A and 15 in group B. There weren´t differences in ECOG status, gender, BMI, age, Charlson score or previous adjuvant treatment (chemotherapy or radiotherapy). Univariate and multivarate analysis didnot show statistically significant differences in survival by GNRI group (p 0.296, p 0.965 respectively). Conclusions: GNRI isnot an independent predictive factor for survival in our cohort. However, sample size, specially in group at greatest risk of malnutrition could explain our results.